Abstract
There were carried out the analysis of anthropometric data and analysis of laboratory parameters (marker of insulin resistance – HOMA-IR index, fasting glucose, glycosylated hemoglobin – НbА1с) in patients diagnosed with «moderate type 2 diabetes mellitus in the stage of decompensation» (60 persons). Depending on the initial laboratory and anthropometric data (fasting glucose level and body mass index) two groups of patients were formed (30 persons per group) to begin the differentiated starting hypoglycemic therapy.The identified indicator analysis has shown that all schemes were effective in patients with type 2 diabetes mellitus who are overweight (BMI 25 kg/m2) or obese. In the patients of the first group, the use of Meglifort (metformin) in combination with a diet has led to a significant reduction of fasting glucose (29.5%) and НbА1с (2.18%), BMI (7%) and HOMA-IR index. The combination of Glinova (glimepiride) and the diet has led to a strong reduction of НbА1с (by 2.8%) and fasting glucose (by 40.6%) in comparison with patients treated with metformin, but BMI and NOMAIR index were not decreased. The schedules of combined oral hypoglycemic therapy along with NPH insulin therapy have shown the high efficacy when were prescribed for the patients with decompensated type 2 diabetes mellitus who are overweight (BMI 25 kg/m2) or obese
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
